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Pharmacologic effects of cannabidiol on acute reperfused myocardial 
infarction in rabbits: evaluated with 3.0T cardiac magnetic  
resonance imaging and histopathology 
 
Abstract  
 
Cannabidiol (CBD) has anti-inflammatory effects. We explored its therapeutic effects on 
cardiac ischemia-reperfusion injury with an experimental imaging platform. Reperfused acute 
myocardial infarction (AMI) was induced in rabbits with a 90-min coronary artery occlusion 
followed by 24-h reperfusion. Before reperfusion, rabbits received two intravenous doses of 
100 μg/kg CBD (n=10) or vehicle (control, n=10). Evans blue was intravenously injected for 
later detection of the AMI-core. Cardiac magnetic resonance imaging (cMRI) was performed 
to evaluate cardiac morphology and function. After euthanasia, blood Troponin I (cTnI) was 
assessed, and the heart was excised and infused with multifunctional red-iodized-oil dye. The 
heart was sliced for digital radiography to quantify the perfusion density rate (PDR), area at 
risk (AAR), and myocardial salvage index (MSI), followed by histomorphologic staining. 
Compared to controls, CBD treatment improved systolic wall thickening (p<0.05), 
significantly increased blood flow in the AAR (p<0.05), significantly decreased 
microvascular obstruction (p<0.05), increased the PDR by 1.7-fold, lowered the AMI-
core/AAR ratio (p<0.05), and increased the MSI (p<0.05). These improvements were 
associated with reductions in serum cTnI, cardiac leukocyte infiltration, and myocellular 
apoptosis (p<0.05). Thus, CBD therapy reduced AMI size and facilitated restoration of LV 
function. We demonstrated that this experimental platform has potential theragnostic utility. 
 
Key words 
Rabbit, myocardial infarction, cMRI, cannabidiol, multifunctional staining 
 
Abstract
1 
 
Pharmacologic effects of cannabidiol on acute reperfused  
myocardial infarction in rabbits: evaluated with 3.0T cardiac magnetic 
resonance imaging and histopathology 
 
Running title: 3.0T cardiac MRI for AMI therapy assessment 
Yuanbo Feng MD, PhD
1,4
; Feng Chen MD, PhD
1,2
;Yin Ting MSc
1
; Qian Xia MD, PhD
1,3
; 
Yewei Liu MSc
1,3
; Gang Huang MD, PhD
3
; Jian Zhang PhD
4
; Raymond Oyen MD, PhD
1
; 
Yicheng Ni MD, PhD
1*  
 
1
KU Leuven, Department of Imaging and Pathology, University Hospital Gasthuisberg,       
Leuven, Belgium 
2
Department of Radiology, the First Affiliated Hospital, Zhejiang University, China 
3
Department of Nuclear Medicine, Ren Ji Hospital, Medical School of Shanghai Jiao Tong 
University, China 
4
Laboratory of Translational Medicine, Jiangsu Academy of Traditional Chinese Medicine, 
Nanjing, China 
 
*Corresponding author 
Prof. Dr. Yicheng Ni MD, PhD, holds Bayer Lecture Chair. 
Radiology, University Hospitals, KU Leuven 
Herestraat 49, 3000 Leuven, Belgium 
Email: yicheng.ni@med.kuleuven.be 
Tel: 0032-16-330165; Fax: 0032-16-343765 
 
Acknowledgements 
This study was partially supported by the EU Asia-Link project CfP 2006-EuropeAid/123738/ 
C/ACT/Multi-Proposal128-498/111, KUL MoSAIC, and IMIR projects.  
Manuscript
2 
 
Conflict of interest 
Authors report no conflicts of interest. 
Reprints:  Prof. Dr. Yicheng Ni MD, PhD, Radiology, University Hospitals, KU Leuven 
Herestraat 49, 3000 Leuven, Belgium. Email: yicheng.ni@med.kuleuven.be 
Tel: 0032-16-330165; Fax: 0032-16-343765 
 
3 
 
Abstract  
Cannabidiol (CBD) has anti-inflammatory effects. We explored its therapeutic effects on 
cardiac ischemia-reperfusion injury with an experimental imaging platform. Reperfused acute 
myocardial infarction (AMI) was induced in rabbits with a 90-min coronary artery occlusion 
followed by 24-h reperfusion. Before reperfusion, rabbits received two intravenous doses of 
100 μg/kg CBD (n=10) or vehicle (control, n=10). Evans blue was intravenously injected for 
later detection of the AMI-core. Cardiac magnetic resonance imaging (cMRI) was performed 
to evaluate cardiac morphology and function. After euthanasia, blood Troponin I (cTnI) was 
assessed, and the heart was excised and infused with multifunctional red-iodized-oil dye. The 
heart was sliced for digital radiography to quantify the perfusion density rate (PDR), area at 
risk (AAR), and myocardial salvage index (MSI), followed by histomorphologic staining. 
Compared to controls, CBD treatment improved systolic wall thickening (p<0.05), 
significantly increased blood flow in the AAR (p<0.05), significantly decreased 
microvascular obstruction (p<0.05), increased the PDR by 1.7-fold, lowered the 
AMI-core/AAR ratio (p<0.05), and increased the MSI (p<0.05). These improvements were 
associated with reductions in serum cTnI, cardiac leukocyte infiltration, and myocellular 
apoptosis (p<0.05). Thus, CBD therapy reduced AMI size and facilitated restoration of LV 
function. We demonstrated that this experimental platform has potential theragnostic utility. 
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Introduction 
Ischemic heart disease is a major cause of mortality and heart failure. Extensive research on 
pharmacological agents has provided therapeutic and interventional solutions.
1
 Moreover, 
advances in imaging technology have played an increasingly important role in translational 
medicine for developing new diagnostics and therapeutics.  
Cannabinoids are the constituents of Cannabis sativa, the plant known as marijuana 
2
. Most 
previous studies on cannabinoids have focused on effects in the central nervous system, 
including the activation of multiple cannabinoid receptors, notably cannabinoid-1 and -2  
(CB1 and CB2) receptors 
3, 4
. Nevertheless, a growing body of evidence has indicated that 
cannabinoids are also associated with beneficial effects on physiopathologies in the 
cardiovascular system 
5, 6
. For example, cannabinoids were found to play a protective role in 
atherosclerosis and myocardial ischemia 
2, 7
.  
Cannabidiol (CBD) is one of the most abundant cannabinoids (Figure 1A). In contrast to the 
major cannabinoid, Δ9-tetrahydrocannabinol, CBD binds very weakly to CB1 and CB2 
receptors, and it does not induce psychoactive or cognitive effects 
5, 8
. However, CBD has 
exhibited multiple pharmacological actions; it has exhibited anxiolytic, antipsychotic, 
antiemetic, antioxidant, anti-inflammatory, and immunomodulatory properties 
8-12
. Moreover, 
CBD is well tolerated and has no known side effects when chronically administered to humans 
9, 10
; thus, it can potentially be safely incorporated into clinical practice. There is also evidence 
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that CBD has positive effects on the cardiovascular system 
13
. When applied directly to isolated 
arteries, CBD caused both acute and time-dependent vasorelaxation 
14
. CBD protected against 
vascular damage by attenuating oxidative/nitrative stress, inflammation, cell death, and 
fibrosis in the high glucose environment of a rat model of type 2 diabetes 
15
. Recently, acute or 
chronic CBD treatment was shown to have little effect on hemodynamics and ischemic cardiac 
arrhythmias, but it protected against ischemia-reperfusion damage, and it reduced the infarct 
size in rats 
2, 7
. CBD influenced the survival, migration, and death of white blood cells, and it 
enhanced platelet aggregation 
13
. Although the precise pharmacological effects of CBD remain 
to be fully elucidated, all these preclinical data appeared to support the notion that CBD could 
be beneficial for treating ischemic heart disease.  
To date, the majority of CBD studies have focused on small rodent models, and CBD has not 
been investigated in medium-sized or large animal models. Few articles have addressed CBD 
therapeutic effects on global and regional cardiac functions and on blood biomarkers specific 
for cardiac damage, like troponin I (cTnI). Furthermore, no study has evaluated how CBD 
might affect other important aspects of heart disease, such as the myocardial area at risk (AAR), 
the myocardial salvage index (MSI), and the myocardial no-reflow phenomenon after 
treatment. Thus, to investigate the role of CBD in ischemic heart disease, it may be necessary 
to work in other animal models. Cardiac magnetic resonance imaging (cMRI) is a widely 
applied noninvasive modality used to make accurate estimates of the infarcted myocardium in 
vivo. In addition, cMRI provides the ability to obtain anatomic and functional data, such as LV 
mass, volumes, cardiac perfusion, and regional and global myocardial functions 
16-18
.  
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The aim of this study was to combine in vivo cMRI and multiple postmortem techniques to 
establish an imaging-based theragnostic platform for evaluating rabbit models of acute 
myocardial infarction (AMI). 
 
Methods 
CBD and dye preparation 
Cannabidiol (Tocris Bioscience, Missouri, USA) was formulated in DMSO:PEG:distilled 
water (1:8:10) and administered intravenously (IV) at 100 µg/kg. Control animals received the 
same volume of vehicle. We prepared two dyes, as described previously 
19, 20
. Briefly, 1% 
Evans blue (EB, Sigma-Aldrich, USA) solution was injected IV at 0.5 ml/kg to specifically 
stain the MI-core in vivo 
20
. In addition, the novel, custom-made dye, called red iodized oil 
(RIO), was prepared by diluting 20 mg oil-red-O dye (Sigma-Aldrich, USA) in 100 ml of 
Lipiodol ultra fluid (Guerbet, France); this was used to determine the AAR ex vivo 
19
. 
Animal model of reperfused AMI 
This experiment was conducted in compliance with the institutional regulations for use and 
care of laboratory animals (Ethische Commissie Dierproeven, KU Leuven, Belgium). 
Rabbit models of AMI were prepared according to a previously introduced method 
16
. Briefly, 
after sedation, tracheal intubation, and mechanical ventilation, rabbits received IV 
pentobarbital (Nembutal, Sanofi Sante Animale, Brussels, Belgium) at 40 mg/kg/h to maintain 
anesthesia for an open-chest operation. The left circumflex coronary artery (LCx) branch was 
7 
 
exposed after opening the pericardium. A 1/2 circle, triangular needle (Sutura, Inc. Fountain 
Valley, CA, USA) with two eyes at the end was used to place 2 silk sutures underneath the LCx. 
These sutures were used to make a removable coronary ligation in vivo and a precise re-ligation 
ex vivo. The thicker 2-0 silk suture was used for the LCx ligation and reperfusion, and the 
thinner 5-0 suture was saved for a later LCx re-occlusion to facilitate multifunctional staining 
20
. The MI was induced by tying the thicker suture with a single detachable knot for 90 min; 
then, the LCx was reperfused by pulling the exteriorized suture loose in closed-chest 
conditions, as previously detailed 
16
. An ECG was performed (Accusync® 71, Milford, 
Connecticut, USA) to confirm the AMI. All animals were allowed to recover, and life was 
sustained until the cMRI scan. 
Experimental protocol 
As illustrated in Figure 1B, 20 rabbits that underwent the experimental AMI-reperfusion 
protocol were randomly assigned into either the CBD treatment group (n=10) or the vehicle 
control group (n=10). Two IV injections of CBD at 100 µg/kg, or equal volumes of vehicle, 
were administered at 10 min before the LCx occlusion and at 10 min before the reperfusion. 
After 20 h, the EB solution was injected IV for postmortem visualization of the AMI-core, and 
10 h later (30 h post-AMI), all animals were subjected to cMRI. They were then sacrificed, and 
blood was collected for a cTnI assessment. The heart was excised for ex vivo cMRI, RIO 
staining, and digital radiography (DR). The cardiac tissues were processed for 
histomorphology.  
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In vivo cMRI 
Rabbits were gas-anesthetized with 2% isoflurane in a mixture of 20% oxygen and 80% room 
air and placed in the supine position in a plastic holder. With an 8-channel phased array knee 
coil, the rabbits were imaged with a 3.0T clinical MRI scanner (Trio, Siemens, Erlangen, 
Germany) with a maximum gradient of 45 mT/m. The cMRI was triggered by both the ECG 
and respiration with a small animal monitoring and gating system (SA Instruments, Inc. Stony 
Brook, New York). Six to 10 consecutive, short-axial slices of the left ventricle (LV) were 
acquired with a slice thickness of 3.0 mm without gaps for all cMRI sequences. Turbo spin 
echo T1WI and T2WI sequences were applied to assess cardiac morphology and edema with 
the following parameters: TR=621/750ms; TE=15/74 ms; FOV=240195 mm²; FA=180°; and 
in-plane resolution=0.90.9 mm². The cine-MR images were acquired in the short-axis, 
vertical long-axis, and horizontal long-axis planes for displaying cardiac contractions. Each 
cine-MRI consisted of 25 frames, spaced equally across the cardiac cycle, with a 2.5 min 
acquisition time. The scan parameters were: TR=357 ms, TE=1.6 ms, FOV=240×195, spatial 
resolution=1.2×0.9 mm2, and flip-angle=60º. After an IV bolus injection of Gd-DOTA 
(Dotarem®, Guerbet, France) at 0.2 mmol/kg, three contiguous short-axis first-pass, 
perfusion-weighted imaging (PWI) were acquired with a segmented turbo-FLASH sequence of 
80 dynamic acquisitions with the following parameters: TR/TE=241.96/1.95 ms; 
FOV=240×180 mm²; TI=150 ms; flip angle=15°; matrix=128×90 mm²; and in-plane 
resolution=1.88×1.98 mm². After 5 and 20 min, the images were acquired for early 
enhancement (EE) and delayed enhancement (DE) cMRIs 
21
 with a 3D segmented k-space 
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inversion recovery turbo-FLASH sequence, with the following parameters: TR=396 ms; 
TE=1.54 ms; TI=360 ms; FOV=240×180 mm²; FA=15°; and in-plane resolution=1.1×0.8 
mm². 
Postmortem procedures 
Cardiac necrosis markers, cardiac Troponin I 
After the cMRI scans were completed, blood was sampled in ethylenediamine-tetraacetic 
acid-coated tubes (Thermo Scientific Pierce, Rockford, USA) and centrifuged (2000 ×g for 15 
min). The plasma samples were frozen and stored at -20 °C until analysis. Plasma levels of 
cTnI were determined with an ELISA kit (R&D, Minneapolis, US). 
Macroscopic multifunctional staining  
EB and RIO dyes were applied to identify the AAR, AMI-core, and the myocardial salvage 
zone (SZ), simultaneously, as described previously 
19, 20
. Briefly, the rabbit was treated with 
heparin before euthanasia; then, a lateral thoracotomy was performed, and the heart was 
excised; a catheter was inserted into the aorta to rinse cardiac vessels with 0.9% saline. After 
re-ligating the LCx branch, 4 ml RIO was infused for 15 min under a pressure of 100 mmHg 
with the injection pump (BD PILOT, Becton Dickinson Infusion System, France). With the 
RIO stain, the normal myocardium appeared brick red, but the AAR remained uncolored; the 
MI-core had previously been stained blue in vivo with the EB dye.  
Ex vivo cMRI  
After RIO infusion, the heart was embedded in a plastic mold with 3% agar and imaged with a 
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high resolution T1WI spin echo sequence (TR/TE=2300/4.12; FOV=512×464 mm²; FA=10°; 
slice thickness=0.5 mm, and in-plane resolution=0.5×0.5 mm²). 
Digital radiography  
The heart was cut to produce 6-8 serial, 3.0-mm slices to match the short axis cMRIs. The 
cardiac slices were exposed at 25 KV/18 mA with a DR mammographic unit (Embrace; 
Agfa-Gevaert, Belgium).   
Tissue processing, histology, and immunohistochemical staining 
Heart sections were fixed with 10% formalin for 24 h. Then, the sections were 
paraffin-embedded, cut into 5-μm slices, and whole-mounted on a standard glass slide. The 
mounted slices were stained with hematoxylin-eosin (HE) and an antiserum (polyclonal rabbit 
anti-human; Dako A0398) specific for neutrophil myeloperoxidase (MPO) 
22
. To study 
apoptosis, slices were stained with a terminal deoxynucleotidyl transferase biotin dUTP nick 
end labeling (TUNEL) kit (Roche Diagnostics, Vilvoorde, Belgium) 
22
. Photomicrographs 
(Axioskop; Zeiss, Oberkochen, Germany, ×100-400) were interpreted by cross-referencing the 
cMRI with the corresponding macroscopic multifunctional staining results. 
Imaging analyses 
The cMRI and postmortem-stained images were analyzed with an off-line workstation 
equipped with dedicated software (SyngoMR A30, Siemens) and software Image J 1.38× with 
the planimetry method 
16
. Analyses were performed by three observers blinded to the study 
protocol. 
11 
 
Myocardial edema, microvascular obstruction, and AMI in vivo 
Myocardial edema and the AMI-core were defined as at least 10 adjacent pixels with signal 
intensities (SIs) greater than 2 SDs above the SI of the remote myocardium on a T2WI, or with 
SIs greater than 5 SDs above the SI of the remote myocardium on a 20-min DE-cMRI 
23
. 
Microvascular obstruction (MVO) was defined on the 5-min EE-cMRI as a dark, 
subendocardial zone inside the enhanced region 
18
. Regions of myocardial edema, the 
AMI-core, and MVO were manually traced, and their volumes were calculated by multiplying 
the diseased areas by the slice thickness. 
LV function  
Quantifications of global and regional LV functions were performed by assessing short-axis 
cine cMRIs with dedicated software (Argus Siemens). The endocardial and epicardial borders 
were manually traced in the end-diastolic and end-systolic short-axis cine images with 
papillary muscles included. We measured the LV end-diastolic volume (EDV), end-systolic 
volume (ESV), stroke volume (SV), ejection fraction (EF), cardiac output (CO), and cardiac 
mass according to standard methods 
16, 21
. Regional LV function was measured by wall 
thickening from the end diastolic phase (Fig 2A, A’) to the end systolic phase (Fig 2B, B’) in 
six clockwise sectors on short-axis cine images, excluding apical and basal slices (Fig 2) 
16
. 
Myocardial perfusion in vivo 
The first-pass PWI was used to evaluate myocardial perfusion. On each of the perfusion images, 
regions of interest in the LV cavity, perfusion-defective regions, and remote normal 
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myocardium were delineated at the first time point, then propagated with epi- and endocardial 
borders, throughout the imaging sequence, with manual adjustments to compensate for overall 
heart motion. We plotted SI-time curves to obtain relative myocardial perfusion values, 
including the time-to-the-peak (TTP) enhancement, the peak intensity value (PIV), the initial 
absolute maximal upslope (ISabs), and the area under the curve (AUC) of the contrast injection. 
All the PWI analyses were implemented in-house in MATLAB® (The MathWorks, Inc., Novi, 
MI). The pre-injection baseline SI was subtracted from the SI-time curve, and subsequently, 
the curves were normalized to the pre-injection baseline to correct signal reception.   
Measurement of perfusion density rate   
The PDR was calculated with the equation:  
PDR = (GVregion of interest – GVblank myocardium density) / GVbackground × 100%,  
where the PDR is the increased signal density that could be purely attributed to RIO dye 
perfusion; the GVregion of interest refers to the mean gray value within the selected area; the GVblank 
myocardium density refers to the averaged gray value from the blank myocardium without the RIO 
dye infusion; and GVbackground represents the mean gray value from the background signal noise 
from the equipment 
19
. The PDRs of the AAR and the normal myocardium were compared to 
determine relative coronary perfusion levels.  
Macroscopic planimetry for standard reference  
For planimetric evaluations of the different treatments, the AMI-core was defined as the 
EB-stained region in the heart sections. The size of the AMI-core was expressed as a 
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percentage (%) of the whole LV volume. The AAR was defined as the non-opaque region on 
the DR and the regions that were not stained with RIO in the heart sections. The AAR was 
expressed as a percentage of the LV. To facilitate comparisons between the different 
treatments, we measured the AAR/LV(%) and the AMI-core/AAR(%) with the multifunctional 
staining method 
20
. The SZ(%) was derived as follows: 
 SZ% = AAR% – MI-core%.  
The MSI was defined as follows: MSI = SZ% / AAR%.  
Microscopic analysis 
Microscopic analyses were performed by a pathologist blinded to the experimental details. On 
sections stained with HE and MPO, Image J software was used to semi-quantify hemorrhages 
and the number of infiltrating neutrophils. The scoring system used a scale of 0 to 3, where 0 
was an absent reaction, 0.5 was a minimal reaction, 1 was a mild reaction observed only at 
high-power magnification, 2 was a moderate reaction observed at low power, and 3 was a 
severe reaction 
22
. 
We also quantified the percentages of apoptotic cells that stained positive with TUNEL (brown 
stain) in the total area of the SZ. For quantification, heart sections were visualized with an 
Axiovert 200 M microscope (Carl Zeiss Inc, Gottingen, Germany), images were captured with 
a Zeiss Axiocam digital camera, and analyses were performed with AxioVision 4.7 software. 
The number of TUNEL-positive cells was counted in 10 high-power fields, randomly selected 
in the SZ. Apoptotic rate was expressed as the percentage of TUNEL-positive nuclei divided 
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by the total number of nuclei. 
Statistics 
Numerical data were expressed as the mean±standard deviation. The statistical analyses were 
performed with Analyse-it® 2.14 for Excel, GraphPad Prism® 5.0. We used ANOVA and 
Bonferroni’s posthoc tests to analyze differences between groups. When data were not 
normally distributed, we performed Kruskal-Wallis nonparametric statistics, and differences 
were identified with Mann-Whitney or Wilcoxon tests. A linear regression was used to 
determine correlations between in vivo and ex vivo evaluations of the therapy. All tests were 
two tailed. A p-value <0.05 was considered statistically significant. 
 
Results 
General aspects 
All rabbits survived the systemic anesthesia, open-chest surgery, and cMRI. None exhibited 
observable toxic or adverse effects after intravenous administration of either the CBD or the 
EB dye. In all cases, the presence of AMI was indicated in vivo with characteristic ECG 
profiles and cMRIs; AMI was confirmed postmortem with the multifunctional staining and 
histopathology. 
Cardiac necrosis markers in blood 
The CBD treatment group had significantly lower peak cTnI (ng/ml) values compared to the 
control group (3.99±1.95 vs. 6.39±2.93; p=0.02). 
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LV function  
The two groups were not significantly different in quantitative parameters of global LV 
function. However, the CBD group tended to show increases compared to controls, 
respectively, in the SV (2.21±0.53 vs. 1.78±0.39 ml), CO (0.27±0.03 vs. 0.20±0.07 l/min), and 
EF (45.36±8.72 vs. 38.93±4.65%). 
On cine cMRIs (Fig. 2A, A’, B, B’), an analysis of regional wall thickening showed that the 
wall motions were impaired on the anterior, lateral, and inferior LV walls compared to the 
normal LV walls in both groups. However, CBD significantly improved the thickening of the 
lateral LV wall (CBD: 34.83±8.15% vs. controls: 25.35±9.89%; p<0.05; Fig 2C).  
Regional perfusion in vivo and perfusion density rate ex vivo 
The first-pass PWI showed a perfusion defect in the LCx region in both groups (Fig 3A, A’). 
The SI-time curves revealed dynamic SI changes within the left ventricular cavity, normal 
myocardium, and AAR (Fig 3B, B’). The two groups showed significant differences in the 
PWI parameters, including the PIV and the AUCs measured at 15, 30, and 45 min (AUC15’, 
AUC30’, and AUC45’; Table 1). These differences indicated that CBD significantly increased 
the relative blood flow in the perfusion-defective region (the AAR; p<0.05).  
The PDRs in the normal myocardium and in the perfusion-deficient region (AAR) were 
examined with DR (Fig 3C, C’). The PDRs were 347.6±33.1% and 30.2±13%, respectively, in 
the control group, compared to 377.2±37.2% and 52.2±14.3%, respectively, in the CBD group. 
The PDR in the AAR was about 1.7 times (52.2/30.2) higher with CBD-treatment than in 
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control conditions. Thus, CBD appeared to increase blood perfusion in the AAR, consistent 
with the in vivo PWI findings.  
Effect of CBD on edema and MVO  
The T2WI results showed a homogeneous, high SI over the culprit vascular regions in both 
groups. Although the two groups showed no significant difference in edema volume (p=0.445), 
the CBD group showed slightly less edema than the controls (43.21±10.81 vs. 46.84±13.44%).  
EE-cMRI showed 15 rabbits with MVO (8 controls, 7 CBD-treated) and 5 without MVO. In 
both groups, relative to small AMIs, the large AMIs tended to be associated with regions of 
“no-reflow” or MVOs. The CBD group showed significantly smaller regions of MVO  
compared to the control group (7.25±2.3% vs. 14.91±4.17%; p=0.01, Fig 4A-C, A’-C’, E). 
This finding was supported by the micro thromboembolisms observed in histological analyses 
(Fig 4D, D’). 
CBD effects on the AAR/LV(%), AMI-core/AAR(%), and MSI 
Transmural hyper-enhanced zones on the DE-cMRIs indicated necrotic AMI-cores (Fig 5A, 
A’), similar to those found on ex vivo DE-cMRIs (Fig 5B, B’) and on EB-stained specimens 
(Fig 5D, D’). The AMI-cores appeared somewhat smaller than the AARs, defined by 
non-opacified regions on the DR (Fig 5C, C’) and by regions not stained with RIO in tissue 
sections (Fig 5D, D’). In the control group, the mean AMI-core/LV (35.35±12.64%) measured 
on in vivo DE-cMRIs correlated well with the ex vivo DE-cMRI findings (34.77±10.38%; 
r
2
=0.95) and the EB-stain findings (33.45±12.21%; r
2
=0.90). In the CBD group, the mean 
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AMI-core/LV (30.45±11.34%) measured on in vivo DE-cMRIs also correlated well with the ex 
vivo DE-cMRI findings (29.89±13.71%; r
2
=0.94) and with the EB-stain findings 
(27.45±10.66%; r
2
=0.92). There were no significant differences between the two groups in the 
AAR/LVs (50.89±15.94% vs. 48.49±16.89%; p=0.85; Fig 6A). However, in the CBD group, 
the AMI-core/AAR was lower than controls (60.51±12.94% vs. 72.66±12.64%, respectively; 
p<0.05; Fig 6B) and the MSI was higher than controls (0.39±0.12% vs. 0.27±0.13%, 
respectively; p<0.05; Fig 6C). Thus, CBD administration significantly reduced the AMI size 
and increased the MSI compared to the vehicle control. 
Histopathological findings 
Macroscopy clearly revealed the hemorrhagic AMI-core in contrast to the lightly-stained 
surrounding myocardium (Fig 5E, E’). Topographically, these results were similar to those 
observed with multifunctional staining (Fig 5D, D’). Microscopy revealed more prominent 
hemorrhages in the AMIs of controls compared to those in the CBD group (Fig 7A, A’). The 
hemorrhage score was lower in CBD-treated than in control rabbits (0.98±0.39 vs. 2.32±0.96; 
p<0.05). In all cases, neutrophils were stained with MPO. The density of MPO-stained 
granules was significantly higher in the control group than in the CBD group (92% vs. 34%, 
p<0.05), which indicated greater neutrophil infiltration in control rabbits (Fig 7B, B’). The cell 
death rate, measured by the number of TUNEL-positive nuclei, was significantly lower in the 
CBD group compared to control rabbits (18% vs. 48%, p<0.05; Fig 7C, C’).  
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Discussion 
Our results showed that two injections of CBD (100 µg/kg), delivered 10 min before LCx 
occlusion and reperfusion, exerted cardioprotective effects on acute ischemia-reperfusion 
injury. The main outcomes of this study were: 1) CBD induced no detectable undesired toxic or 
psychological effects ; 2) CBD decreased the blood cTnI levels; 3) CBD increased blood flow 
in the AAR, and thus, preserved some cardiac functions; 4) CBD reduced the AMI-core/AAR% 
and increased the MSI; 5) CBD provided protection from reperfusion injury, and this 
protection was associated with reductions in infiltrating neutrophils and MPO activity; and 6) 
we successfully evaluated the therapeutic effects of CBD on an occlusion/reperfusion rabbit 
model, based on our previously established technical platform. 
Ischemia-reperfusion injury is a major problem after AMI. The treatment options are limited, 
but they are evolving with research in both in vitro and in vivo models 
1, 24
. CBD is a 
non-psychotropic constituent of the Cannabis sativa (marijuana) plant, which was reported to 
exert antioxidant and anti-inflammatory effects, both in vitro and in various preclinical models 
of neurodegenerative and inflammatory disorders 
8-12
. The effects of CBD are independent of 
those found in conventional approaches that targeted CB1 and CB2 receptors 
25
. Both 
prolonged and transient CBD administrations have demonstrated cardioprotective effects, but 
only in rat models 
2, 7
. The present study was the first to test CBD in medium-sized animals 
(rabbits) with a myocardial occlusion/reperfusion insult. We showed that two consecutive 
CBD injections provided acute cardioprotection by increasing the regional blood flow, 
19 
 
improving the wall thickness, and attenuating the AMI size.  
Our dosing protocol was similar to that used previously by Walsh et al., 
7
 except that we 
doubled each CBD dose from 50 to 100 µg/kg; this dose was deemed clinically-relevant and its 
safety was supported by the fact that rabbits tolerated this higher dose well without observable 
side effects. In a review, Bergamaschi et al. 
9
 found that chronic CBD administrations and high 
doses up to 1500 mg/day were well-tolerated in humans.  
Cardiac troponins regulate contractile function in striated muscle. Their presence in the blood 
indicates cardiac damage 
26, 27
. Indeed, cTnI is uniquely expressed in the heart, and it provides 
a specific biomarker of AMI 
27
. The diagnostic value of cTnI has been rarely studied in animals 
with AMI that received CBD treatment. In our study, the blood cTnI level significantly 
decreased after CBD treatment, which indicated the cardioprotective effect of CBD. 
Furthermore, we observed that neutrophil migration and MPO activity were significantly 
reduced in CBD-treated rabbits. These findings may be attributable to a protective effect of 
CBD on the microvasculature. MPO is a good surrogate for tissue neutrophil activity, which 
occurs predominantly under pathological conditions 
28
. MPO-associated tissue damage was 
probably inhibited by CBD, which contributed to a reduction in myocardial inflammation. 
The cMRI noninvasively provides abundant morphological information about myocardial 
edema, and it reveals the location, transmurality, and size of AMIs, MVOs, and 
intramyocardial hemorrhages. Moreover, the cMRI facilitates accurate assessments of global 
and regional LV functions. Currently, the cMRI represents the most powerful phenotyping tool 
for comprehensive evaluation of post-infarction remodeling 
29
. In this study, the cMRI was 
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applied mainly to evaluate therapeutic effects on cardiac function and perfusion, because the 
morphology could be quantified with standard postmortem techniques. Although CBD did not 
significantly improve global LV function, it significantly increased the thickness of the lateral 
wall in the dominant region affected by the LCx. The first-pass PWI offered dynamic 
information about the passage of the Gd-contrast agent through the entire heart. This technique 
was used to assess blood perfusion in the ischemic versus the normal myocardium, which 
formed the basis of the perfusion reserve indices 
17
. More recently, the perfusion reserve has 
been estimated from the AUC of the myocardial SI over time, up to the observation of the first 
pass peak in the blood. This AUC served as an indicator of myocardial blood flow, and it was 
previously validated against microsphere measurements 
17, 30
. We performed semi-quantitative 
measurements of the parameters derived from myocardial SI-curves, and we found that CBD 
therapy significantly increased the PIV and AUC within the AAR, from baseline to 15, 30, and 
45 min. Therefore, CBD seemed to improve microvascular flow, which was consistent with 
our observations of reduced MVO and increased regional wall thickening. 
The mechanisms of action for CBD remain obscure. CBD reportedly reduced brain damage 
and improved functional recovery after acute hypoxia-ischemia in newborn pigs 
31
. Other 
groups have indicated that CBD had anti-inflammatory effects in a murine model of acute lung 
injury, and that the effect was associated with an increased supply of extracellular adenosine, 
which stimulated signaling through adenosine A2A receptors 
28
. Moreover, several studies 
have shown that CBD was beneficial in preventing ischemia-reperfusion damage. In the liver, 
ischemia/reperfusion caused significant elevations in alanine aminotransferase, hepatic 
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malondialdehyde, tumor necrosis factor-alpha, and nitric oxide levels. CBD counteracted those 
effects by attenuating inflammatory signaling and responses, oxidative and nitrative stress, and 
cell death 
25, 32
, and by significantly reducing the expression of inducible nitric oxide synthase 
32
. Liu et al showed that increasing the nitric oxide levels could improve microvascular flow 
and decrease AMI size after myocardial ischemia and reperfusion in pigs 
22
.  
CBD was also found to bind to PPARγ and stimulate the differentiation of 3T3-L1,1 fibroblasts 
into adipocytes 
14
. Ligand-activated PPARγ increased anti-inflammatory cytokines, inhibited 
inducible nitric oxide synthase expression 
33
, and decreased the inflammatory response in 
cardiovascular cells, particularly endothelial cells 
34
. Furthermore, CBD decreased monocyte 
adhesion and transendothelial migration. These properties indicated that CBD may provide 
significant therapeutic benefits to patients with diabetic complications and atherosclerosis 
35
.  
In 2007, Durst and colleagues showed that in vivo treatment with CBD significantly reduced 
the AMI size in rats, and this was associated with a reduction in infiltrating leucocytes and 
circulating interleukin (IL)-6 
2
. In 2010, Walsh et al. subsequently showed that a single IV dose 
of CBD at 50 mg/kg, given 10 min pre-ischemia or 10 min pre-reperfusion, could significantly 
reduce the infarct size 
7
. This effect was associated with a reduction in ventricular ectopic beats, 
which suggested that CBD might also act as an anti-arrhythmic agent. Also in 2010, Rajesh et 
al. showed that, after 11-weeks of in vivo CBD treatment (20 mg/kg, i.p.), diabetic mice 
showed significant reductions in cardiac dysfunction. This effect was associated with reduced 
myocardial inflammation, oxidative stress, nitrative stress, and fibrosis, mediated by reduced 
nuclear factor-κB activation, reduced mitogen-activated protein kinase activation, and reduced 
22 
 
expression of adhesion molecules and tumor necrosis factor 
15
. In the present study, although 
we measured fewer biochemical markers, we confirmed the cardioprotective effects of CBD in 
a rabbit ischemic-reperfusion model. The role of CBD may be related to the above-mentioned 
mechanisms, but they need to be verified further.  
Methodologically, the experimental techniques introduced and applied in this study provided 
specific staining of the AMI-core with EB dye and clear visualization of the AAR. The DR 
showed a filling defect, and ROI staining indicated the damaged, non-stained regions on heart 
sections; moreover, the whitish areas indicated salvageable myocardium on heart sections. 
This study had some limitations. First, our attempts to image the contracting rabbit heart with a 
clinical MR scanner proved technically challenging; the artifacts from respiratory movements 
and heartbeats could not be completely eliminated. Second, we did not attempt to evaluate 
AAR and MSI with in vivo cMRI scans, which are thought to be clinically crucial. Third, the 
CBD dosage protocol requires optimization to maximize the therapeutic effects of CBD. 
 
Conclusion 
In this study, we demonstrated that cMRI could be used to monitor, noninvasively, the 
beneficial effects of the newly-identified cardioprotective agent, CBD, on a rabbit model of 
AMI. In addition, our multifunctional staining method demonstrated that CBD treatment 
reduced the size of ischemic injury in the myocardium.  
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Figures legends 
 
Figure 1. Introduction to cannabidiol (CBD) and the study protocol. A: Introduction to the Cannabis 
sativa plant and the chemical structure of CBD. B: A flowchart of the study protocol. 
 
Figure 2. Comparison of LV wall thickening between control and CBD groups. 
LV end diastolic (A, A’) and systolic (B, B’) cine short-axis images from CBD-treated and control 
groups. We segmented the LV wall into six equal sectors to evaluate wall thickening. The blue and 
red dashed-lines correspond to control and CBD groups on the histogram. Sectors 1-3 show decreased 
wall thicknesses in both groups, but CBD significantly increased the wall thickness in sector 2. Sector 
1: left anterior wall; Sector 2: lateral wall; Sector 3: left inferior wall; Sector 4: right inferior wall; 
Sector 5: septal wall; and Sector 6: right anterior wall. *p<0.05 indicates a significant difference 
between groups  
 
Figure 3. In vivo myocardial first-pass perfusion (PWI) and ex vivo perfusion digital radiography (DR) 
for control and CBD groups. (A, A’) The PWI showed a perfusion deficit after the LCx occlusion and 
reperfusion insult, which was larger in (A) the control group than in (A’) the CBD group. (B and B’) 
SI-time curves indicate slower and lower contrast enhancement in the AAR compared to that in the 
normal myocardium (NM) and in the ventricular cavity (VC); perfusion was slightly increased in the 
CBD group. (C and C’) The DRs showed that the AAR of the control group was larger than that of the 
CBD group. The AAR detected with in vivo PWI was a good match to that detected with the ex vivo 
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DR in both groups. 
 
Figure 4. Evaluation of microvascular obstruction (MVO) with cMRI and histomorphology. 
(A, B, C) The MVOs from base to apex in the control group were apparently larger than (A’, B’, C’) 
those in the CBD group. (D, D’) HE-stained micrographs showed severe MVO with more 
thromboembolic material in the microcirculation of (D) control animals compared to (D’) 
CBD-treated animals. (E) The histograms of cMRI data indicate that CBD significantly decreased 
MVO. 
 
Figure 5. Comparison of large hemorrhagic AMIs between control (upper row) and CBD (lower row) 
groups. (A, A’) On DE-cMRIs, transmural AMIs appeared hyperenhanced, which corresponded well 
to (B, B’) ex vivo DE-cMRI findings; (C, C’) with DR, AARs are shown as perfusion deficits; (D, D’) 
with RIO-staining, AARs appear as negative regions. The EB-stained, dark blue MI-cores within the 
RIO-negative AARs became apparently smaller after CBD therapy; (E, E’) HE-stained photographs 
confirmed the CBD effect on AARs..  
 
Figure 6. Effect of CBD on the AAR/LV (%), AMI-core/AAR (%), and myocardial salvage index 
(AAR–AMI-core)/AAR), defined by multifunctional staining. (A) There was no significant difference 
between the two groups in the AAR/LV (%). (B) CBD significantly decreased the AMI size, based on 
the AMI-core/AAR (%), and (C) CBD increased the MSI. *p <0.05 significant difference between 
groups 
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Figure 7. Histochemical staining of myocardial sections treated with or without CBD. (A, A’) HE 
staining shows severe hemorrhage in the infarct zone of (A) a control heart section, but not (A’) in a 
CBD-treated heart section. (B, B’) Myeloperoxidase (MPO) immunostaining in the AAR indicates 
abundant neutrophil infiltration in (B) the control heart, but less severe in (B’) the CBD-treated heart. 
(C, C’) TUNEL staining indicates numerous apoptotic myocytes in the AAR of (C) control hearts, but 
much less in (C’) the CBD-treated hearts. Original magnifications: (A, A’) ×100, (B, B’) ×200, and 
(C, C’) ×400 
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Table 1. Evaluation on myocardial perfusion after therapy. 
 
       Ventricle cavity   Normal myocardium  Perfusion deficit (AAR) 
 Control CBD  Control CBD  Control CBD 
PIV: (SI) 13.14±1.67 12.75±1.69  6.42±1.03 6.52±1.21  3.66±1.82 5.22±2.21* 
TTP(sec) 8.68±3.3 7.16±1.89  14.19±6,08 12.45±5.87  53.32±19.1 46.79±20,32 
ISabs(SI/sec) 87.72±32.11 86.13±35.06  37.86±14.49 40.85±21.78  14.73±5.68 17.81±7.73 
AUC15(SI*sec) 114.07±26.52 120.89±22.62  52.55±12.69 55.21±10.16  23.22±7.31 32.29±10.22* 
AUC30(SI*sec) 233.39±33.81 234.41±20.63  121.78±18.65 126.97±18.22  59.76±17.57 83.64±20.23* 
AUC45(SI*sec) 355.86±38.97 363.30±38.73  187.43±37.09 201.22±30.27  99.17±21.95 148.92±32.63* 
 
Data are presented as mean ± SD. PIV: peak intensity value; SI: signal intensity; TTP: time to 
peak; ISabs: initial absolute maximal upslope; AUC15, AUC30, AUC45: area under curves from 
base to 15’, 30’ and 45’. 
*: P<0.05 obtained from a two-way ANOVA and Bonferroni post hoc test indicates a significant 
difference. 
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